Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

BACKGROUND: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. OBJECTIVES: To assess the efficacy and safety of ofatumumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315184/
https://www.ncbi.nlm.nih.gov/pubmed/35266417
http://dx.doi.org/10.1177/13524585221078825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315184/
https://www.ncbi.nlm.nih.gov/pubmed/35266417
http://dx.doi.org/10.1177/13524585221078825

Ejemplares similares